Table 3.

Other Studies of CSII for T2DM

Reference	na	Design	Therapy	Follow-up	Primary end point	Primary result
Edelman et al.9	58	Longitudinal	CSII simple dosing	4 months	HbA1c	Significant reduction in HbA1c
Jennings et al.10	20	RCT	CSII or conventional insulin	4 months	HbA1c	Significant reduction in HbA1c favoring CSII
Kapitza et al.11	6	Feasibility	CSII with simple insulin pump	7 days	Glycemic profiles	Stable or improved glycemic profiles
Labrousse-Lhermine et al.12	59	Longitudinal	CSII simple dosing, two regimens	3 years	HbA1c	Significant reduction in HbA1c for 2 CSII regimens
Lane13	9	Feasibility	CSII with U-500 insulin	3 months	HbA1c	Significant reduction in HbA1c
Parkner et al.14	21	Crossover	Basal CSII or insulin glargine	2 periods of 8 days	Insulin and glycemic profiles	Improved insulin and glycemic profiles favoring CSII
Testa et al.15	126	RCT	CSII or MDI	24 weeks	Treatment satisfaction	Improved treatment satisfaction favoring CSII

^aSubjects randomized.